千红制药: 股票交易异常波动公告

Group 1 - The company's stock experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days (July 16, 2025, July 17, 2025, and July 18, 2025) [1] - The board of directors conducted a verification regarding the abnormal trading situation and confirmed that there are no undisclosed significant information or major events in planning stages that could impact the stock [1][2] - The actual controller's concerted actor, Mr. Wang Ke, increased his shareholding by 22,000,000 shares through block trading, representing 1.72% of the company's total share capital [1] Group 2 - The board confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange's regulations, nor any information that could significantly affect the company's stock price [2] - The company has not identified any need to correct or supplement previously disclosed information [2]